Answers are grounded in this paper and cite their sources.
Introduction: Diabetes mellitus (DM) is probably one of the oldest diseases known to man. It was rst reported in Egyptian manuscript about 3000 years ago.1 In 1936, the distinction between type 1 and type 2 DM was clearly made.2 Type 1diabetes is an autoimmune reaction that attacks cells in your pancreas that produce insulin and is caused by inherited genetics or environmental elements. Type 2 diabetes happens when your body becomes resistant to insulin and is associated with genetics and lifestyle changes. Diabetes is fast gaining the status of a potential epidemic in India, with 69.2 million people living with diabetes (8.7%). Of these, more than 36 million people remained undiagnosed.3 It is predicted that by 2030 diabetes mellitus may afict up to 79.4 million individuals in India.4,5 The current scenario of diabetes in India is likely to worsen in the coming decade. The greatest numbers of people with diabetes are between 40 and 59 years of age.6 Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with a global prevalence of 20%-40%. Approximately 40%-60% of patients with type 2 diabetes mellitus (DM2) experience NAFLD; out of which 20%-40% cases may have higher severity. Due to the scarcity of available reports from the eastern part of India, we aimed to evaluate the effects of dapagliozin. Material and Method: - This was hospital-based study, randomized, active –controlled, open label study, Place of study was Departments of Medicine, and Gastroenterology and Hepatology, Dr. Rajendra Prasad Government Medical College, and Hospital, Kangra at Tanda. This was hospital-based study, randomized, active –controlled, open label study, Place of study was Departments of Medicine, and Gastroenterology and Hepatology, Dr. Rajendra Prasad Government Medical College, and Hospital, Kangra at Tanda. The study included consecutive patients with DM2 and NAFLD, treated with dapagliozin at 10 mg daily for six months. All patients underwent detailed anthropometric, biochemical, abdominal ultrasonography, and transient elastography studies at baseline and after therapy as well as a comparative analysis. Results:- In the 100 patients included in our study, the male and female patients (male-to- female ratio, 1:1.17). There was no signicant difference in gender based distribution. The mean age at presentation was 55.86 ± 9.52 years. The mean body mass index signicantly decreased over the course of the therapy, from at baseline 26.21 ± 1.51 kg/m2 to 24.02± 4.03 kg/m2 after the therapy. The patients' transaminitis, dyslipidemia, and glycemic status signicantly improved over the course of the therapy. We also observed signicant (p < 0.05) improvement in hepatic steatosis by the end of the treatment. Although transient elastography by Fibro Scan-measured hepatic brosis score (Echosens, Paris, France) signicantly decreased from 9.81 ± 1.23 to 6.1 ± 1.07 kpa, hepatic brosis did improve signicantly (p ≥ 0.05) following therapy. Conclusion:- Although dapagliozin improved body mass index, transaminitis, dyslipidemia, glycemic status, and hepatic steatosis, it had also shown effect on hepatic brosis.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: